Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP Sells $166,729.08 in Stock

Key Points

• Alphatec Holdings, Inc. EVP Craig E. Hunsaker sold 10,876 shares for a total of $166,729.08, reducing his holding to 1,389,142 shares valued at approximately $21.3 million.
• The company's recent quarterly earnings report showed earnings per share (EPS) of $0.02, exceeding estimates and achieving a 27.5% year-over-year revenue growth.
• Equities analysts have set a consensus target price of $18.50 for Alphatec, with several firms maintaining a "buy" rating on the stock.

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) EVP Craig E. Hunsaker sold 10,876 shares of the business's stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $15.33, for a total transaction of $166,729.08. Following the transaction, the executive vice president owned 1,389,142 shares of the company's stock, valued at approximately $21,295,546.86. This trade represents a 0.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Alphatec Trading Down 2.0%

Shares of NASDAQ ATEC traded down $0.30 during midday trading on Thursday, reaching $14.90. 4,026,670 shares of the stock were exchanged, compared to its average volume of 2,697,044. The company has a market capitalization of $2.20 billion, a P/E ratio of -13.19 and a beta of 1.05. The company has a current ratio of 2.88, a quick ratio of 1.77 and a debt-to-equity ratio of 23.22. Alphatec Holdings, Inc. has a 52-week low of $4.88 and a 52-week high of $15.46. The stock has a 50 day moving average price of $11.58 and a 200-day moving average price of $11.26.

Alphatec (NASDAQ:ATEC - Get Free Report) last issued its earnings results on Thursday, July 31st. The medical technology company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.08. Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 24.33%. The business had revenue of $185.54 million for the quarter, compared to analyst estimates of $178.85 million. During the same period last year, the company posted ($0.29) EPS. The business's quarterly revenue was up 27.5% on a year-over-year basis. Equities research analysts expect that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Institutional Trading of Alphatec

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Nuveen LLC acquired a new stake in shares of Alphatec during the first quarter worth $135,874,000. Vanguard Group Inc. increased its stake in Alphatec by 0.8% during the first quarter. Vanguard Group Inc. now owns 6,014,772 shares of the medical technology company's stock valued at $60,990,000 after acquiring an additional 45,792 shares during the period. American Century Companies Inc. boosted its holdings in Alphatec by 16.9% during the first quarter. American Century Companies Inc. now owns 5,830,031 shares of the medical technology company's stock valued at $59,117,000 after purchasing an additional 840,974 shares in the last quarter. Royal Bank of Canada increased its holdings in shares of Alphatec by 10.8% during the first quarter. Royal Bank of Canada now owns 3,527,939 shares of the medical technology company's stock worth $35,773,000 after buying an additional 342,656 shares in the last quarter. Finally, Nuveen Asset Management LLC lifted its position in shares of Alphatec by 78.4% during the fourth quarter. Nuveen Asset Management LLC now owns 2,584,996 shares of the medical technology company's stock worth $23,730,000 after purchasing an additional 1,136,330 shares in the last quarter. 66.35% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have issued reports on ATEC shares. HC Wainwright reissued a "buy" rating and set a $20.00 price target on shares of Alphatec in a research report on Monday, April 14th. Needham & Company LLC reiterated a "buy" rating and set a $16.00 price objective on shares of Alphatec in a research note on Friday, May 2nd. Piper Sandler reissued an "overweight" rating and set a $15.00 price objective (up previously from $13.00) on shares of Alphatec in a research note on Friday, May 2nd. Lake Street Capital upgraded shares of Alphatec to a "buy" rating and set a $18.00 price target for the company in a research report on Monday, June 16th. Finally, Canaccord Genuity Group reiterated a "buy" rating and issued a $20.00 price objective on shares of Alphatec in a research note on Friday, August 1st. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, Alphatec currently has an average rating of "Moderate Buy" and a consensus target price of $18.50.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.